AONC — American Oncology Network Income Statement
0.000.00%
- $50.01m
- $189.83m
- $1.28bn
Annual income statement for American Oncology Network, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 725 | 944 | 1,150 | 1,279 |
Cost of Revenue | ||||
Gross Profit | 77.4 | 94.2 | 95.5 | 82.8 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 703 | 943 | 1,144 | 1,328 |
Operating Profit | 22.1 | 0.911 | 5.57 | -49.2 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 21.2 | 0.355 | 2.59 | -62.5 |
Provision for Income Taxes | ||||
Net Income After Taxes | 22 | -0.105 | 2.59 | -62.9 |
Minority Interest | ||||
Equity in Affiliates | ||||
Net Income Before Extraordinary Items | ||||
Net Income | 0 | 0 | 0 | -5.54 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 0 | 0 | 0 | -9.12 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 0 | 0 | 0 | 1.67 |